FLT3 and acute myeloid leukemia: Past work in our lab has shown that FLT3/ITD AML cells treated with FLT3 TKI experience an initial inhibition of ERK signaling followed by a reactivation of ERK that starts within a few hours after commencing TKI treatment [14].